This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

GM-CSF in Patients With Pulmonary Alveolar Proteinosis

This study has been terminated.
Information provided by:
FDA Office of Orphan Products Development Identifier:
First received: January 30, 2002
Last updated: March 24, 2015
Last verified: January 2002
This is a study to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).

Condition Intervention Phase
Pulmonary Alveolar Proteinosis Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Trial of GM-CSF for Alveolar Proteinosis

Resource links provided by NLM:

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment: 48
Study Start Date: September 2001
Estimated Study Completion Date: December 2005
Detailed Description:

PAP is a rare lung disease characterized by accumulation of surfactant phospholipids and proteins within the lungs. There is no specific pharmacologic therapy for PAP and the current practice of lung lavage under general anesthesia is invasive and has limitations. Although it is unknown if the anti GM-CSF antibody is related to the disease pathogenesis, observations suggest a role for GM-CSF in lung homeostasis as well as in the pathogenesis of PAP.

Patients will receive subcutaneous GM-CSF or placebo once a day and will be followed on an outpatient basis at 2 weeks, and 1, 2, 3, 4, 5 and 6 months after initiation of therapy. Clinical response will determine dosing schedule and will be evaluated by symptom scores, gas exchange data, and chest radiographs.

Completion date provided represents the completion date of the grant per OOPD records


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Diagnosis of primary or idiopathic PAP
  • Creatinine no greater than 2 mg/dL
  • Bilirubin no greater than 2 mg/dL
  • Liver enzymes no greater than 3 times normal
  • Women must use an effective method of contraception, be post menopausal, or be surgically sterilized

Exclusion criteria:

  • Active respiratory infection
  • Active cardiovascular disease (e.g., cardiogenic pulmonary edema)
  • Underlying myeloproliferative disorder or leukemia
  • Other secondary cause of PAP (e.g., occupational exposure to silica or HIV with PCP)
  • At increased risk of side effects from GM-CSF therapy (i.e., rheumatoid arthritis, immune thrombocytopenia, or autoimmune thyroiditis)
  • Previous therapy with GM-CSF
  • Pregnant or nursing
  • Significant renal or liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00030056

United States, Colorado
National Jewish Medical Center
Denver, Colorado, United States
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
The University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Sponsors and Collaborators
The Cleveland Clinic
  More Information Identifier: NCT00030056     History of Changes
Other Study ID Numbers: FD-R-002016
Study First Received: January 30, 2002
Last Updated: March 24, 2015

Keywords provided by FDA Office of Orphan Products Development:
Injections, Subcutaneous

Additional relevant MeSH terms:
Pulmonary Alveolar Proteinosis
Lung Diseases
Respiratory Tract Diseases processed this record on September 21, 2017